VAXCYTE, INC. Finance Lease, Liability, Current
VAXCYTE, INC. (PCVX) had Finance Lease, Liability, Current of $0 as of 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2021-03-29
- 2020-12-31: Finance Lease, Liability, Current $0.00.
| Period end | Finance Lease, Liability, Current |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |